Feb 9 (Reuters) - Regenxbio said on Monday the U.S. Food and Drug Administration had declined to approve its gene therapy for ...

After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by ...

Life Biosciences is pushing cellular rejuvenation into the clinic with ER-100, an experimental gene ...

The FDA in July last year declined to approve UX111 for Sanfilippo syndrome, a rare neurodegenerative disorder, citing ...

Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru crafted a bespoke treatment that has successfully corrected the genetic ...

The Food and Drug Administration has rejected a rare-disease gene therapy from Regenxbio, the company said Monday.

A research team has successfully demonstrated the world's first gene-editing treatment for Leber's hereditary optic ...

Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to ...

The Food and Drug Administration paused trials for two experimental gene therapies from Regenxbio after one child developed a ...

Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...

Gene therapy holds the promise of preventing and curing disease by manipulating gene expression within a patient's cells.

Gene therapy is a medical treatment that works by changing or fixing a person's genes to treat or prevent disease ...